Relmada Therapeutics Inc (RLMD : NASDAQ)
Common Stock
$4.22
USD
+0.00 (%)
Last updated: 2026-09-17
Get RLMD alerts:
RLMD
Relmada Therapeutics Inc
WealthAwesomePerformance
1 Day
-4.95%
1 Week
+3.18%
1 Month
-11.53%
YTD
-36.06%
Key Statistics
Market Cap
$450.15M
52W High
$8.00
52W Low
$1.47
P/E Ratio
-
50 Day MA
$5.03
200 Day MA
$5.48
Beta
0.45
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $4.28 | $4.39 | $4.18 | $4.20 | $4.20 | 772,911 |
| 9/16/2026 | $4.45 | $4.57 | $4.21 | $4.22 | $4.22 | 824,376 |
| 9/15/2026 | $4.44 | $4.50 | $4.30 | $4.44 | $4.44 | 1,998,635 |
| 9/14/2026 | $4.52 | $4.56 | $4.42 | $4.44 | $4.44 | 1,264,731 |
| 9/11/2026 | $4.60 | $4.65 | $4.29 | $4.52 | $4.52 | 2,629,279 |
| 9/10/2026 | $4.25 | $4.25 | $4.00 | $4.07 | $4.07 | 2,808,981 |
| 9/9/2026 | $4.24 | $4.28 | $4.09 | $4.09 | $4.09 | 1,590,041 |
| 9/8/2026 | $4.40 | $4.42 | $4.13 | $4.25 | $4.25 | 1,697,806 |
| 9/4/2026 | $4.35 | $4.44 | $4.32 | $4.43 | $4.43 | 675,555 |
| 9/3/2026 | $4.55 | $4.58 | $4.33 | $4.37 | $4.37 | 847,511 |
Analyst Price Targets
Based on 3 analysts covering RLMD · as of Sep 17, 2026
Wall Street analysts forecast RLMD stock price to rise 193.8% over the next 12 months.
Consensus
Hold3.00 / 5.00
Avg. Target
US$12.40
+193.8% Upside
Current Price
US$4.22
Last close
Analyst Breakdown (3 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RLMD's historical volatility
30-Day Vol
58.3%
Annualized
90-Day Vol
58.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$3.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$3.96 | US$3.24 – US$4.84 |
| 60 trading days | US$3.73 | US$2.81 – US$4.95 |
| 90 trading days | US$3.51 | US$2.48 – US$4.98 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-13.86M
- Profit Margin
- 0.00%
- ROE (TTM)
- -55.66%
- EPS (Diluted)
- -0.91
- Book Value
- 10.15
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About RLMD.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |